WCN26-5205 REAL-WORLD ANEMIA MANAGEMENT BEFORE HEMODIALYSIS INITIATION IN JAPAN: A RETROSPECTIVE MULTICENTER COHORT STUDY

Read full text Summarise with VIRAT
Authors: Hideka Miyauchi, Yu Mihara, Minato Umehara, Kunihiro Nakai, Hozue Ehara, Tomoharu Ida, Yayoi Shiotsu, Kazuhiro Sonomura, Keiichi Tamagaki
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Anemia is a common complication of chronic kidney disease (CKD) and contributes to the progression of both CKD and heart failure. Although current guidelines recommend maintaining hemoglobin (Hb) within the target range, Hb levels often decline progressively under uremic conditions in advanced CKD. In Japan, five hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have been approved since 2021, expanding therapeutic options for anemia management. HIF-PHIs are expected to enhance iron utilization and may be effective in patients with hyporesponsiveness to erythropoiesis-stimulating agents (ESAs).

Fields of Study & Subjects

Erythropoietin and Anemia Treatment Dialysis and Renal Disease Management Iron Metabolism and Disorders

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104235–104235
Publication date
25 March 2026
Language
EN